researches and develops leading ophthalmic disease treatment drugs to meet the unmet needs of a large number of patients and continuously create social welfare.
, an ophthalmic biotechnology company dedicated to the development of global innovative therapies, Dianjing Biomedical Technology (Suzhou) Co., Ltd. (Dianjing Bio), today announced the completion of a US$50 million Series A financing. The financing was jointly led by Eli Lilly Asia Fund, Hillhouse Ventures, , and Spring Capital. The headquarters and R&D center of Dianjing Biology are located in Suzhou Industrial Park, with a business center in Shanghai, and plans to establish an international clinical and registration center in the San Francisco Bay Area of the United States. Dr. Zhang Jinzhong, co-founder, chairman and CEO of
, said: “We are very grateful for the support and trust of three internationally renowned investment institutions. The company will use these funds to establish a global innovative R&D pipeline and core ophthalmic innovation technology platform to meet The medical needs of patients in China and the world for eye diseases. At the same time, we are very happy to hire three internationally renowned ophthalmologists, Professor Quan Dong Nguyen from Stanford University, Professor Liu Zuguo from Xiamen University and Professor Sun Xiaodong from Shanghai Jiaotong University as Dianjing Members of the first scientific advisory committee of Biology, and thank them for their suggestions and help in formulating company strategy and R&D pipelines.” Z3z
Hillhouse Capital Co-Chief Investment Officer and Head of Hillhouse Ventures Biomedicine and Medical Devices said:
“
With increasing aging, changing lifestyles, increasing overuse of eyes, and increasing public health awareness, the incidence of eye diseases in China has been on the rise in recent years. However, the technical requirements for ophthalmic drug research and development are high, and new drugs have been approved in China Less, domestic patients have a large number of unmet needs. The founding team of Dianjing Bio has rich drug development capabilities and continuous innovation capabilities, and has great potential in the future. Hillhouse will help Dianjing Bio to continue to innovate and research and develop leading ophthalmic disease treatments Medicines meet the unmet needs of a large number of patients and continuously create social well-being.
"
Dianjing Bio is co-founded by Eli Lilly Asia Foundation and two returnees. Dr. Zhang Jinzhong is a doctor of science jointly cultivated by Peking University and Kyoto University, Japan. He was an assistant professor of ophthalmology at the Case Western Reserve University School of Medicine in the United States and the principal investigator of a project funded by the Institute of Ophthalmology of the National Institutes of Health in the United States. Japan's Santen Pharmaceuticals and Graybug Vision, an American ophthalmology start-up company recently listed on NASDAQ, hold senior leadership positions and have participated in the research and development of a number of listed ophthalmic innovative products. Dr. Hu Zhenze received a bachelor's degree and a doctorate degree in pharmacy from China Pharmaceutical University and the University of Michigan. He has been focusing on the field of ophthalmology for more than 20 years, focusing on the research and development, clinical needs, international regulations, technology transfer and market analysis of ophthalmic products at home and abroad Has a wealth of experience. At the same time,
announced that Dr. Charles Semba (Xianbo) was invited to join Dianjing Biotech as the chief medical officer. Dr. Xianbo is an internationally renowned expert in the development of new ophthalmic drugs. He previously served as the chief medical officer of three ophthalmology companies: SARcode Bioscience (acquired by Shire/Takeda), ForSight VISION5 (acquired by Allergan) and Graybug Vision (NASDAQ: GRAY). He also served as the Vice President of Ophthalmology at Shire/Takeda and the Head of Ophthalmology Clinical Development at Gegentech. Dr. Xianbo successfully led the clinical development of the world's first blockbuster antibody drug Lucentis (LUCENTIS) for the treatment of wet age-related macular degeneration and the first new type of dry eye drug XIIDRA that simultaneously improves symptoms and signs. The core team of
also includes two members who have made achievements in ophthalmology translational medicine and clinical management. Dr. Weiyong Shen is an ophthalmologist trained in China and Australia, and served as the vice president of research at Dianjing Bio; he has more than 25 years of experience in basic and translational research on retinal diseases, and has published more than 90 in the fields of ophthalmology and neuroscience Papers. Dr. Mei Li served as the vice president of clinical operations in Dianjing Bio; she has more than 20 years of experience in clinical trial management in China, and has made important contributions to the clinical research and registration of several imported ophthalmic products from Allergan (China) .
About Eluminex Bioscien
Eluminex Biosciences Limited) was established in February 2020 and is a biomedical company specializing in ophthalmic diseases. Dianjing Bio is led by an experienced team, aiming to establish an innovative and sustainable ophthalmic product pipeline to solve unmet clinical needs and benefit patients with eye diseases in China and around the world. The company headquarters and R&D center are located in Suzhou Industrial Park, with a business center in Shanghai, and plans to establish an international clinical and registration center in the San Francisco Bay Area.
GLV About Hillhouse Ventures
Hillhouse Ventures (GL Ventures) is Hillhouse's venture capital fund focusing on early-stage innovative companies, mainly specialized in biomedicine and medical equipment, software and hardware technology, consumer Internet and technology, emerging Venture investment in the four major areas of consumer brands and services. The fields of biomedicine and medical devices have always been Hillhouse's key investment directions. For more than a decade, Hillhouse has invested in more than 200 outstanding companies in biomedicine, medical devices and medical services. We hope to work with companies and be friends of time, and jointly promote the innovation and development of companies in the big health field, and benefit more patients.
5 rounds raise! Perfect Diary goes public, Hillhouse Ventures is the largest institutional investor
